LLY · News · 20260817N

Competition and market share - oral GLP-1

ELI LILLY & Co · 2026-08-17 · Importance 30 · Surprise 42

Foundayo received UK approval for weight management and type 2 diabetes, making it the second GLP-1 pill approved in Europe after Novo Nordisk’s Wegovy. Lilly is positioning Foundayo’s convenience, including no food restrictions, to narrow Novo Nordisk’s lead in European patient numbers and market penetration. The approval intensifies competition in the rapidly expanding European weight-loss drug market, although Wegovy retains a significant head start.

Key facts